2cureX AB Total Assets
2cureX AB total assets. Based on the latest financial reports, 2cureX AB (2CUREX) holds total assets worth Skr5.18 Million SEK (≈ $557.02K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 2CUREX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of 2cureX AB (2015–2024)
Total assets of 2cureX AB from 2015 to 2024. This chart illustrates how 2cureX AB's total assets have evolved over time, based on quarterly financial data. See latest 2cureX AB stock price today for real-time trading data and today's change.
2cureX AB - Asset Composition Analysis
2cureX AB Total Assets Breakdown (December 2024)
2cureX AB total assets breakdown as of December 2024. 2cureX AB's total assets of Skr5.18 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 66.4% |
| Accounts Receivable | Skr2.56 Million | 33.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how 2cureX AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 2cureX AB current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 2cureX AB's current assets represent 100.0% of total assets in 2024, an increase from 92.1% in 2015.
- Cash Position: Cash and equivalents constituted 66.4% of total assets in 2024, up from 51.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 33.1% of total assets.
2cureX AB Competitors by Total Assets
Key competitors of 2cureX AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
2cureX AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.51 | 3.33 |
| Quick Ratio | 1.14 | 1.51 | 3.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr626.00K | Skr2.18 Million | Skr23.42 Million |
2cureX AB - Advanced Valuation Insights
This section examines the relationship between 2cureX AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.84 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -52.4% |
| Total Assets | Skr7.75 Million |
| Market Capitalization | $1.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values 2cureX AB's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 2cureX AB's assets decreased by 52.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 2cureX AB (2015–2024)
The table below shows the annual total assets of 2cureX AB from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr7.75 Million ≈ $833.70K |
-52.41% |
| 2023-12-31 | Skr16.28 Million ≈ $1.75 Million |
-65.84% |
| 2022-12-31 | Skr47.66 Million ≈ $5.13 Million |
-39.80% |
| 2021-12-31 | Skr79.16 Million ≈ $8.52 Million |
+25.56% |
| 2020-12-31 | Skr63.04 Million ≈ $6.78 Million |
+66.60% |
| 2019-12-31 | Skr37.84 Million ≈ $4.07 Million |
+57.50% |
| 2018-12-31 | Skr24.03 Million ≈ $2.59 Million |
+5.17% |
| 2017-12-31 | Skr22.85 Million ≈ $2.46 Million |
+110.72% |
| 2016-12-31 | Skr10.84 Million ≈ $1.17 Million |
-10.15% |
| 2015-12-31 | Skr12.07 Million ≈ $1.30 Million |
-- |
About 2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.